查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464773

出血性疾病診斷市場：按診斷測試、適應症和最終用途分類 - 全球預測 2024-2030

Bleeding Disorder Diagnostics Market by Diagnostic Tests (Bleeding Time, Genetic Tests, Platelet Aggregation Tests), Indication (Hemophilia A & Hemophilia B, Platelet Function Disorders, Von Willebrand Disease), End-use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

出血性疾病診斷市場規模預計2023年為6.6287億美元，2024年達到7.1026億美元，預計2030年將達到11.0709億美元，複合年成長率為7.60%。

出血性疾病診斷包括用於識別和評估異常出血的根本原因的各種醫學測試和程序。這些疾病，無論是先天性的還是後天性的，都會影響血液正常凝固的能力，導致輕傷導致長時間出血，嚴重時會導致無明顯原因的自發性出血。出血性疾病的診斷方法涉及臨床評估和實驗室測試的組合。這些診斷的目的是準確診斷特定類型的出血性疾病，評估其嚴重程度，並指導適當的治療和管理策略。準確的診斷對於實施有效的治療和提高出血性疾病患者的生活品質至關重要。全球出血性疾病的盛行率不斷增加，以及患者對這些疾病早期診斷重要性的認知不斷提高，增加了對出血性疾病診斷的需求。然而，先進診斷測試的高成本可能會普及其在低收入地區的可用性，而農村和低度開發地區缺乏熟練的專業人員可能會限制其可用性。儘管存在這些挑戰，旨在提高診斷準確性和降低成本的持續研究和開發工作為提高全球出血性疾病診斷的可近性和普及提供了新的成長途徑。

主要市場統計
基準年[2023] 66287萬美元
預測年份 [2024] 71026萬美元
預測年份 [2030] 1,107.09百萬美元
複合年成長率（%） 7.60%

診斷測試：識別與凝血因子相關的特定基因的突變和異常的基因測試將變得越來越重要。

出血時間是一種傳統的診斷測試，旨在評估初步止血情況，通常評估在前臂下側切開小切口後血管止血所需的時間。此測試反映了血小板與血管壁的相互作用，但不直接測量凝血因子活性。出血性疾病基因檢測分析人類的 DNA，以識別導致出血性疾病的基因異常或突變。這些檢查對於診斷遺傳性出血性疾病特別有用，例如A型血友病和乙型血友病、馮·維勒布蘭德病和其他罕見的凝血因子缺乏症。基因檢測提供明確的診斷，支持基因帶原檢測，深入了解疾病的嚴重程度，並指南治療決策。血小板凝集測試是一系列測試，用於評估血小板（一種對血液凝固很重要的血球）聚集形成血塊的程度。這些檢驗評估血小板針對各種凝聚劑（例如 ADP、膠原蛋白、瑞斯托菌素和腎上腺素）的功能。

適應症：出血性疾病診斷對診斷不同類型VWD的重要應用

A型血友病，也稱為經典血友病，是一種由凝血因子VIII缺乏引起的遺傳性疾病。這種疾病會導致受傷或手術後過度或自發性出血，尤其是肌肉和關節。它發生在男性中，並以 X 連鎖隱性方式遺傳。 B型血友病，也稱為聖誕節病，是由凝血因子 IX 缺乏引起的。其臨床症狀與A型血友病相似，但較少見。血小板功能障礙是一組以血小板無法有效促進血液凝固，導致異常出血為特徵的疾病。這些疾病可能是先天性的，例如格蘭茲曼血栓無力或伯納德-蘇利埃症候群，也可能是由於其他醫療狀況或藥物引起的。症狀包括傷口流血過多、容易瘀青和長時間流血。血小板計數測試、血小板功能檢查和出血時間測試通常用於診斷這些疾病。馮·維勒布蘭氏症(VWD) 是一種常見的遺傳性出血性疾病，由馮·維勒布蘭德因子(VWF) 功能障礙或缺乏引起，馮·維勒布蘭德因子是血栓形成的關鍵蛋白。根據 VWF 的數量或品質缺陷，VWD 可分為三種主要類型。患者可能會出現自發性出血、外傷或外科手術期間出血過多或月經期間大量出血。 VVD 的診斷很複雜，包括評估患者的出血史、VWF 抗原檢測以及評估 VWF 和因子 VIII 活性的功能測試。

區域洞察

在美洲，尤其是北美，出血性疾病診斷市場正在經歷強勁成長。美國因其高度發展的醫療基礎設施、大量的研發投資以及主要市場參與企業的強大影響力而成為這一成長的主要貢獻者。大量的A型血友病和B型血友病血友病患者以及支持性報銷政策進一步增強了該地區出血性疾病診斷的需求。歐洲、中東和非洲地區由於不同的經濟、醫療和監管情況，呈現不同的市場表現。由於高意識、強大的醫療保健系統以及對出血性疾病診斷的大量投資，歐洲保持了強勁的市場成長。然而，儘管中東和非洲的成長率有所放緩，但在發展醫療基礎設施和改善診斷機會的支持下，成長率正在逐漸上升。由於醫療保健支出的增加和提高醫療保健標準的努力，中東地區的前景尤其樂觀。由於人口眾多、醫療成本不斷上升以及對出血性疾病的認知不斷提高，亞太地區已成為出血性疾病診斷快速成長的市場。由於醫療基礎設施的擴大、出血性疾病數量的增加以及政府為改善醫療服務所做的努力，該地區的新興國家正在迅速採用出血性疾病診斷解決方案。

FPNV定位矩陣

FPNV 定位矩陣對於評估出血性疾病診斷市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對出血性疾病診斷市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動以及突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.出血性疾病診斷市場的市場規模與預測為何？

2.在出血性疾病診斷市場的預測期間內，有哪些產品、細分市場、應用和細分市場需要考慮投資？

3.出血性疾病診斷市場的技術趨勢和法規結構是什麼？

4.出血性疾病診斷市場主要供應商的市場佔有率為何？

5. 進入出血性疾病診斷市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 出血性疾病盛行率增加
      • 公眾和醫療保健專業人員對出血性疾病的認知和承諾正在不斷增強
    • 抑制因素
      • 與先進的出血性疾病診斷方法相關的高成本
    • 機會
      • 尖端技術診斷出血性疾病的新可能性
      • 更多採用照護現場出血性疾病檢測設備
    • 任務
      • 不同地區醫療保健監管的複雜性與動態性
  • 市場區隔分析
    • 診斷測試：用於識別與凝血因子相關的特定基因的突變和異常的基因測試變得越來越重要。
    • 適應症：出血性疾病診斷對於診斷各類VWD的重要應用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章出血性疾病診斷市場：透過診斷測試

  • 介紹
  • 出血時間
  • 基因檢測
  • 血小板凝集試驗

第7章出血性疾病診斷市場：依適應症分類

  • 介紹
  • A型血友病 A和B型血友病
  • 血小板功能障礙
  • 血管性血友病

第8章出血性疾病診斷市場：依最終用途分類

  • 介紹
  • 診斷實驗室
  • 醫院
  • 專科診所

第9章美洲出血性疾病診斷市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太出血性疾病診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章：歐洲、中東和非洲出血性疾病診斷市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-8E373E9E2067

[198 Pages Report] The Bleeding Disorder Diagnostics Market size was estimated at USD 662.87 million in 2023 and expected to reach USD 710.26 million in 2024, at a CAGR 7.60% to reach USD 1,107.09 million by 2030.

Bleeding disorder diagnostics encompass a range of medical tests and procedures used to identify and evaluate the underlying causes of abnormal bleeding. These disorders, which can be either congenital or acquired, affect the blood's ability to coagulate properly, leading to prolonged bleeding even from minor injuries or, in severe cases, spontaneous bleeding without any apparent cause. Diagnostic approaches for bleeding disorders include a combination of clinical assessments and laboratory testing. The goal of these diagnostics is to accurately diagnose the specific type of bleeding disorder, assess its severity, and guide appropriate treatment and management strategies. Accurate diagnosis is crucial for implementing effective treatments and improving the quality of life for individuals with bleeding disorders. The rising prevalence of bleeding disorders worldwide, coupled with a growing awareness among patients about the importance of early diagnosis of these conditions, is bolstering the need for bleeding disorder diagnostics. However, the high cost of advanced diagnostic tests, which may limit their accessibility in low-income regions, and the shortage of skilled professionals in rural and underdeveloped areas pose significant challenges to the widespread adoption of these diagnostic solutions. Despite these challenges, ongoing research and development activities aimed at enhancing diagnostic accuracy and reducing costs offer new growth avenues for improved accessibility and adoption of bleeding disorder diagnostics worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 662.87 million
Estimated Year [2024] USD 710.26 million
Forecast Year [2030] USD 1,107.09 million
CAGR (%) 7.60%

Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors

Bleeding time is a traditional diagnostic test designed to evaluate primary hemostasis and assess the duration it takes for blood vessels to cease bleeding after a small incision, typically on the underside of the forearm. It reflects the interaction between platelets and the vascular wall but does not measure clotting factor activity directly. Genetic testing in the context of bleeding disorders involves analyzing an individual's DNA to identify genetic abnormalities or mutations that may lead to a bleeding disorder. These tests are particularly valuable for diagnosing inherited bleeding disorders, including hemophilia A and B, Von Willebrand disease, and other rare clotting factor deficiencies. Genetic tests provide definitive diagnoses, enable carrier testing, offer insights into disease severity, and guide treatment decisions. Platelet aggregation tests are a suite of assays used to evaluate how well platelets, a type of blood cell crucial for clotting, clump together to form a blood clot. These tests assess the function of platelets in response to various aggregating agents such as ADP, collagen, ristocetin, and epinephrine.

Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD

Hemophilia A, also referred to as classical hemophilia, is a genetic disease caused by a deficiency of clotting factor VIII. This condition leads to excessive bleeding following injury or surgery and spontaneous bleeding episodes, notably in muscles and joints. It affects males, being passed on through an X-linked recessive pattern. Hemophilia B, also called Christmas disease, is caused by a deficiency of clotting factor IX. Its clinical manifestations are similar to Hemophilia A, though it is less common. Platelet function disorders are a group of conditions characterized by the inability of platelets to effectively contribute to blood clotting, leading to abnormal bleeding. These disorders can be congenital, such as Glanzmann thrombasthenia or Bernard-Soulier syndrome, or acquired due to other medical conditions or medications. Symptoms include excessive bleeding from wounds, easy bruising, and prolonged bleeding times. Diagnosis of these disorders typically involves platelet count tests, platelet function assays, and bleeding time tests. Von Willebrand Disease (VWD) is one of the common inherited bleeding disorders caused by a dysfunction or deficiency of the von Willebrand factor (VWF), a major protein in blood clot formation. VWD is categorized into three main types based on the quantitative or qualitative defect of VWF. Patients may experience spontaneous bleeding, excessive bleeding during injury or surgical procedures, and heavy menstrual bleeding. Diagnosis of VVD is complex and includes evaluating the patient's bleeding history, VWF antigen tests, and functional assays to assess the activity of VWF and factor VIII.

Regional Insights

In the Americas, particularly in North America, the market for bleeding disorder diagnostics is experiencing robust growth. The United States contributes majorly to this growth with a highly advanced healthcare infrastructure, significant investments in R&D, and a strong presence of major market players. A significant number of hemophilia A & hemophilia B patients and supportive reimbursement policies further fuel the need for bleeding disorder diagnostics in the region. The EMEA region shows a diverse market performance owing to varying economic, healthcare, and regulatory landscapes. Europe maintains a strong market growth with high awareness levels, strong healthcare systems, and significant investments in bleeding disorders diagnostics. However, growth rates in the Middle East and Africa are slower but gradually increasing, driven by efforts to improve healthcare infrastructure and access to diagnostics. The Middle East, in particular, shows promise with rising healthcare expenditure and initiatives to enhance healthcare standards. The APAC region is emerging as a rapidly growing market for bleeding disorder diagnostics, attributed to its large population base, increasing healthcare expenditure, and growing awareness of bleeding disorders. Emerging economies in the region are rapidly adopting bleeding disorder diagnostics solutions owing to their expanding healthcare infrastructure, rise in bleeding disorders, and initiatives by governments to improve healthcare access.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bleeding Disorder Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bleeding Disorder Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorder Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Baxter International Inc., Bayer AG, Bio-Rad Laboratories, Inc., Cepheid by Danaher Corporation, CSL Limited, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Hyphen BioMed by Sysmex Corporation, Laboratory Corporation of America Holdings, Novo Nordisk A/S, Precision BioLogic, rHEALTH, Siemens AG, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Tests
    • Bleeding Time
    • Genetic Tests
    • Platelet Aggregation Tests
  • Indication
    • Hemophilia A & Hemophilia B
    • Platelet Function Disorders
    • Von Willebrand Disease
  • End-use
    • Diagnostic Laboratories
    • Hospitals
    • Specialized Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bleeding Disorder Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bleeding Disorder Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Bleeding Disorder Diagnostics Market?

4. What is the market share of the leading vendors in the Bleeding Disorder Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Bleeding Disorder Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bleeding disorders
      • 5.1.1.2. Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with advanced bleeding disorder diagnostics methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging potential of advanced technologies in bleeding disorder diagnostics
      • 5.1.3.2. Growing adoption of point-of-care bleeding disorder testing devices
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities and the dynamic nature of healthcare regulations across different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors
    • 5.2.2. Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bleeding Disorder Diagnostics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Bleeding Time
  • 6.3. Genetic Tests
  • 6.4. Platelet Aggregation Tests

7. Bleeding Disorder Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Hemophilia A & Hemophilia B
  • 7.3. Platelet Function Disorders
  • 7.4. Von Willebrand Disease

8. Bleeding Disorder Diagnostics Market, by End-use

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialized Clinics

9. Americas Bleeding Disorder Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bleeding Disorder Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ARUP Laboratories Makes History with Diagnostic Test for Hemophilia A
    • 12.3.2. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BLEEDING DISORDER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 285. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023